Heidelberg Pharma Announces Financial Figures for Fiscal Year 2019 and Provides Business Update
- Preparation of the clinical trial with HDP-101 advanced
- Material supply of partners with Amanitin established
- Partnership with Magenta opens up new areas of application for ATAC technology
- Pivotal Phase III trial initiated by collaboration partner Telix
- Significant year-over-year revenue growth
- Financing commitment of up to EUR 15 million from main shareholder dievini
- Conference call to be held on 19 March 2020 at 3:00 p.m. CET
Heidelberg Pharma AG today published its financial results and annual report for fiscal year 2019 (1 December 2018 – 30 November 2019) and its outlook for 2020.